Today’s Stock On Watch: What’s Propelling Alder Biopharmaceuticals Inc to Increase So Much?

Today's Stock On Watch: What's Propelling Alder Biopharmaceuticals Inc to Increase So Much?

The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is a huge mover today! About 297,293 shares traded hands. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has declined 11.33% since April 22, 2016 and is downtrending. It has underperformed by 16.74% the S&P500.
The move comes after 9 months positive chart setup for the $1.36B company. It was reported on Nov, 25 by Barchart.com. We have $28.02 PT which if reached, will make NASDAQ:ALDR worth $95.20 million more.

Analysts await Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to report earnings on February, 28. They expect $-0.87 EPS, down 45.00% or $0.27 from last year’s $-0.6 per share. After $-0.70 actual EPS reported by Alder Biopharmaceuticals Inc for the previous quarter, Wall Street now forecasts 24.29% negative EPS growth.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Ratings Coverage

Out of 9 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alder Biopharmaceuticals has been the topic of 11 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was reinitiated by Wells Fargo on Thursday, April 21 with “Outperform”. The stock has “Outperform” rating given by Credit Suisse on Tuesday, March 29. The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has “Buy” rating given on Wednesday, April 20 by Brean Capital. The stock has “Overweight” rating given by Piper Jaffray on Monday, October 31. The firm has “Buy” rating by Jefferies given on Wednesday, September 9. The firm has “Overweight” rating by JP Morgan given on Tuesday, September 13. As per Wednesday, July 27, the company rating was maintained by Jefferies.

According to Zacks Investment Research, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.”

More news for Alder Biopharmaceuticals Inc (NASDAQ:ALDR) were recently published by: Fool.com, which released: “Why Alder Biopharmaceuticals Is Sky-Rocketing Today” on March 28, 2016. Globenewswire.com‘s article titled: “Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2016 …” and published on October 20, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment